AbbVie's Experimental Therapy Shows Reduction in Type of Lung Cancer in Phase 2 Study

By Colin Kellaher AbbVie said Wednesday that a Phase 2 study of its experimental drug telisotuzumab-vedotin, or teliso-V, showed a reduction in disease in...

Related Keywords

Colin Kellaher , ,Article Normal ,Biotechnology Services ,Pharmaceuticals ,Cancer Drugs ,Healthcare Life Sciences ,Biopharmaceuticals ,Specialized Drugs Medications ,New Products Services ,Research Development ,Corporate Industrial News ,Products Services ,New Product Service Testing ,Cancer ,Political General News ,Respiratory Tract Diseases ,Health ,Respiratory Tract Cancer ,Medical Conditions ,Content Types ,Factiva Filters ,C Amp Ampe Industry News Filter ,Synd ,Abbvie ,Abbv ,Us00287y1091 ,New Products ,Services ,Research ,Development ,Corporate ,Industrial News ,Products ,New Product ,Service Testing ,Political ,General News ,Healthcare ,Life Sciences ,Specialized Drugs ,Medications ,